NCT03797001View on ClinicalTrials.gov

Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

July 22, 2024

Study Completion Date

July 22, 2024

Conditions
Heart Failure, SystolicInflammation
Interventions
DRUG

Anakinra

100 mg subcutaneous injection, daily for 24 weeks

DRUG

Placebo

subcutaneous injection, daily for 24 weeks

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER

NCT03797001 - Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2 | Biotech Hunter | Biotech Hunter